Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor. Sequence: D-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr. IC50 & Target: CD4, HIV^[1] In Vitro: Peptide T acts to block viral entry as it inhibits in the MAGI cell assay and blocks infection in the luciferase reporter assay using HIV virions pseudotyped with ADA envelope. Peptide T selectively inhibits HIV replication using chemokine receptor CCR5 compared to CXC4^[2]. Peptide T at 10^-8 M induces IL-10 production by the human Th2 cell line and PBMC. Also peptide T at 10^-9 M concentration significantly inhibits IFN-g production by PBMC^[3]. In Vivo: Peptide T is administered subcutaneously at different doses and phases of the experimental autoimmune encephalomyelitis (EAE) disease, but Peptide T neither prevents nor ameliorates EAE^[4].